GlassScriptPhysician profile
James L Amato
NPI 1689627267
$1,788.42
in general payments reported to CMS, 2019-2025
19 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $92.30 · 2021: $181 · 2022: $41.21 · 2023: $548 · 2024: $520 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $410.63 | 2019-2025 | Zoom Wireless Transmitter, Cds - Mct/Cem Monitoring |
| Genzyme Corporation | $394.49 | 2023-2024 | |
| Exact Sciences Corporation | $160.70 | 2023-2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $133.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $123.70 | 2023 | Xarelto |
| Allergan, INC. | $122.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.58 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $64.07 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $52.82 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $39.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.13 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.00 | 2020 | |
| Atricure, INC. | $29.82 | 2024 | |
| Itamar Medical INC | $20.88 | 2023 | Watchpatone |
| Heartflow, INC. | $19.12 | 2023 | Ffrct |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.98 | 2021 | |
| Shockwave Medical, INC | $17.96 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Pfizer INC. | $14.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.